Company profile COGT

Cogent Biosciences Inc
Description of the company is not available.
Quarter analysis & expected interestLast update: February 08 2024 19:03:52.

After 39 days of this quarter the interest is at 180.0. Based on that we can calculate that during remaining 52 days it will total up to 420.0.
Cogent Biosciences expected interest is significantly higher compared to previous quarter (+117.6%) and same quarter last year (+281.8%).

YearQ1Q2Q3Q4
201954
15
-72.2% QoQ
54
260.0% QoQ
60
11.1% QoQ
2020 21
-61.1% YoY -65.0% QoQ
21
40.0% YoY 0.0% QoQ
70
29.6% YoY 233.3% QoQ
125
108.3% YoY 78.6% QoQ
2021 132
528.6% YoY 5.6% QoQ
149
609.5% YoY 12.9% QoQ
132
88.6% YoY -11.4% QoQ
145
16.0% YoY 9.8% QoQ
2022 104
-21.2% YoY -28.3% QoQ
221
48.3% YoY 112.5% QoQ
215
62.9% YoY -2.7% QoQ
62
-57.2% YoY -71.2% QoQ
2023 110
5.8% YoY 77.4% QoQ
151
-31.7% YoY 37.3% QoQ
173
-19.5% YoY 14.6% QoQ
193
211.3% YoY 11.6% QoQ
2024 180
63.6% YoY -6.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cogent Biosciences search interestLast update: February 08 2024 19:03:51.
Correlation coefficient between keyword and revenue is -0.38
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 19:03:53.

The average 5 years interest of Cogent Biosciences was 9.15 per week.
The last year interest of Cogent Biosciences compared to the last 5 years has changed by 55.3%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 303.69%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 19:04:00.

After 39 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 52 days it will total up to 47.0.
Cogent Biosciences stock expected interest is significantly lower compared to previous quarter (-58.4%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201985
25
-70.6% QoQ
25
0.0% QoQ
83
232.0% QoQ
2020 76
-10.6% YoY -8.4% QoQ
0
-100.0% YoY -100.0% QoQ
76
204.0% YoY inf% QoQ
113
36.1% YoY 48.7% QoQ
2021 160
110.5% YoY 41.6% QoQ
202
inf% YoY 26.2% QoQ
220
189.5% YoY 8.9% QoQ
60
-46.9% YoY -72.7% QoQ
2022 113
-29.4% YoY 88.3% QoQ
152
-24.8% YoY 34.5% QoQ
117
-46.8% YoY -23.0% QoQ
124
106.7% YoY 6.0% QoQ
2023 71
-37.2% YoY -42.7% QoQ
108
-28.9% YoY 52.1% QoQ
229
95.7% YoY 112.0% QoQ
113
-8.9% YoY -50.7% QoQ
2024 20
-71.8% YoY -82.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cogent Biosciences stock search interestLast update: February 08 2024 19:03:59.
Correlation coefficient between keyword and revenue is -0.12
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 19:04:01.

The average 5 years interest of Cogent Biosciences stock was 8.32 per week.
The last year interest of Cogent Biosciences stock compared to the last 5 years has changed by 21.39%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 91.65%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Bezulcastinib to provide analysis

Correlation between past revenue and Bezulcastinib search interest

There is not enough data for Bezulcastinib to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Bezulcastinib to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 05 2023 00:04:39.

After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 91
2019 101
11.0% QoQ
223
120.8% QoQ
40
-82.1% QoQ
69
-24.2% YoY 72.5% QoQ
2020 89
-11.9% YoY 29.0% QoQ
73
-67.3% YoY -18.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2021 0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2022 0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2023 0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Systemic mastocytosis treatment search interestLast update: November 05 2023 00:04:39.
Correlation coefficient between keyword and revenue is 0.4
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 05 2023 00:04:40.

The average 5 years interest of Systemic mastocytosis treatment was 2.63 per week.
The last year interest of Systemic mastocytosis treatment compared to the last 5 years has changed by -100.0%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -100.0%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Gastrointestinal stromal tumor therapy to provide analysis

Correlation between past revenue and Gastrointestinal stromal tumor therapy search interest

There is not enough data for Gastrointestinal stromal tumor therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Gastrointestinal stromal tumor therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precision therapies for genetic diseases to provide analysis

Correlation between past revenue and Precision therapies for genetic diseases search interest

There is not enough data for Precision therapies for genetic diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precision therapies for genetic diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 00:06:45.

After 39 days of this quarter the interest is at 273.0. Based on that we can calculate that during remaining 52 days it will total up to 637.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019419
598
42.7% QoQ
538
-10.0% QoQ
603
12.1% QoQ
2020 688
64.2% YoY 14.1% QoQ
633
5.9% YoY -8.0% QoQ
510
-5.2% YoY -19.4% QoQ
475
-21.2% YoY -6.9% QoQ
2021 665
-3.3% YoY 40.0% QoQ
494
-22.0% YoY -25.7% QoQ
418
-18.0% YoY -15.4% QoQ
532
12.0% YoY 27.3% QoQ
2022 521
-21.7% YoY -2.1% QoQ
546
10.5% YoY 4.8% QoQ
685
63.9% YoY 25.5% QoQ
565
6.2% YoY -17.5% QoQ
2023 676
29.8% YoY 19.6% QoQ
486
-11.0% YoY -28.1% QoQ
586
-14.5% YoY 20.6% QoQ
532
-5.8% YoY -9.2% QoQ
2024 273
-59.6% YoY -48.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Biotechnology companies search interestLast update: February 09 2024 00:06:44.
Correlation coefficient between keyword and revenue is -0.25
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 00:06:47.

The average 5 years interest of Biotechnology companies was 43.84 per week.
The last year interest of Biotechnology companies compared to the last 5 years has changed by -0.55%.
The interest for Biotechnology companies is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by -5.65%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Cogent Biosciences Massachusetts to provide analysis

Correlation between past revenue and Cogent Biosciences Massachusetts search interest

There is not enough data for Cogent Biosciences Massachusetts to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Cogent Biosciences Massachusetts to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 19:04:12.

After 39 days of this quarter the interest is at 134.0. Based on that we can calculate that during remaining 52 days it will total up to 313.0.
Cogent Biosciences -stock -company expected interest is significantly higher compared to previous quarter (+142.6%) and same quarter last year (+154.5%).

YearQ1Q2Q3Q4
20190
94
inf% QoQ
25
-73.4% QoQ
21
-16.0% QoQ
2020 76
inf% YoY 261.9% QoQ
18
-80.9% YoY -76.3% QoQ
49
96.0% YoY 172.2% QoQ
59
181.0% YoY 20.4% QoQ
2021 143
88.2% YoY 142.4% QoQ
129
616.7% YoY -9.8% QoQ
34
-30.6% YoY -73.6% QoQ
84
42.4% YoY 147.1% QoQ
2022 110
-23.1% YoY 31.0% QoQ
199
54.3% YoY 80.9% QoQ
139
308.8% YoY -30.2% QoQ
101
20.2% YoY -27.3% QoQ
2023 123
11.8% YoY 21.8% QoQ
104
-47.7% YoY -15.4% QoQ
120
-13.7% YoY 15.4% QoQ
129
27.7% YoY 7.5% QoQ
2024 134
8.9% YoY 3.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cogent Biosciences -stock -company search interestLast update: February 08 2024 19:04:12.
Correlation coefficient between keyword and revenue is -0.38
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 19:04:13.

The average 5 years interest of Cogent Biosciences -stock -company was 7.25 per week.
The last year interest of Cogent Biosciences -stock -company compared to the last 5 years has changed by 40.0%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 216.2%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for COGT
Earnings date: 2024-03-12 After close
Company name: Cogent Biosciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-12T13:30:00Z

GlobeNewswire
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

2026-05-06T12:06:04Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55

2026-05-05T12:00:00Z

GlobeNewswire
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

2026-04-21T12:00:00Z

GlobeNewswire
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

2026-04-17T12:00:00Z

GlobeNewswire
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-01T12:00:00Z

GlobeNewswire
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

2026-03-17T12:31:35Z

Analyst Upgrades
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

2026-03-16T12:00:00Z

GlobeNewswire
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

2026-02-28T14:45:00Z

GlobeNewswire
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

2026-02-18T12:29:31Z

Analyst Upgrades
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52

2026-02-17T13:00:00Z

GlobeNewswire
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

2026-02-10T13:00:00Z

GlobeNewswire
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

2026-01-26T13:00:00Z

GlobeNewswire
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

2026-01-21T13:54:47Z

Analyst Upgrades
Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

2026-01-20T13:00:00Z

GlobeNewswire
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)